Allison Gatlin (@ibd_agatlin) 's Twitter Profile
Allison Gatlin

@ibd_agatlin

Biopharma and medtech reporter for Investor's Business Daily, @IBDinvestors. @Cronkite_ASU alumna, taco connoisseur and twin mom. She/her.

ID: 3300865039

linkhttp://investors.com calendar_today29-07-2015 19:22:19

7,7K Tweet

7,7K Followers

0 Following

Allison Gatlin (@ibd_agatlin) 's Twitter Profile Photo

$BLUE won FDA approval for Zynteglo, a gene therapy for beta thalassemia patients dependent on regular blood transfusions. investor.bluebirdbio.com/news-releases/…

Allison Gatlin (@ibd_agatlin) 's Twitter Profile Photo

$AXSM is up 34% right now after winning FDA approval for its depression treatment. I recently wrote about the late-stage pipeline in depression. investors.com/news/technolog…

Allison Gatlin (@ibd_agatlin) 's Twitter Profile Photo

The White House is preparing to transfer financial responsibility for Covid shots and treatments to consumers. $PFE $MRNA $BNTX $MRK $GILD $JNJ $NVAX investors.com/news/technolog…

Allison Gatlin (@ibd_agatlin) 's Twitter Profile Photo

Much to the horror of my husband, I taught the twins how to knock on doors. But I didn't teach them to stop when someone doesn't answer. 🤣

Allison Gatlin (@ibd_agatlin) 's Twitter Profile Photo

$AXSM surges after winning FDA approval for a new depression drug. It's an oral NMDA receptor agonist, the first of its kind. investors.com/news/technolog…

Albert Bourla (@albertbourla) 's Twitter Profile Photo

In June, we shared that we are developing a bivalent Omicron BA.4/BA.5-adapted vaccine. I’m excited to update that we completed our EUA submission to U.S. FDA today, and plan to complete our EMA submission in the coming days: on.pfizer.com/3QXMg6T

Allison Gatlin (@ibd_agatlin) 's Twitter Profile Photo

My husband and I almost had a collective panic attack watching this. (I had some childbirth complications.) The word "torture" is apt. I used that word to describe this scene after watching it.

Allison Gatlin (@ibd_agatlin) 's Twitter Profile Photo

When you email a PR person ENDLESSLY about a specific topic... only to see him quoted in another publication about said topic (after ghosting you for a month). Yes, this is a subtweet. Yes, I'm bitter.

Allison Gatlin (@ibd_agatlin) 's Twitter Profile Photo

Two of the best-rated biotech stocks are also among the worst performers today. Here's why. $APLS $BLTE investors.com/news/technolog…